Anti-Human Prolactin (Clone 172) – HRP

Purified Recombinant Human Prolactin (>98%)

This horseradish peroxidase conjugate is supplied in a specially formulated stabilization diluent.(Leinco Prod. No.: S509)

Stable for at least one year when stored at 2°C - 8°C. Do not freeze.

Paired with Leinco Prod. No. P101, Clone No. 174: Pro 100%, BhCG < 1%, ihCG < 1%, LH <1%, FSH < 1%. Paired with Leinco Prod. No. P102, Clone No. 180: Pro 100%, BhCG < 1%, ihCG < 1%, LH <1%, FSH < 1%.

Next Day 2-8°C

Mouse Anti-Human Prolactin (Clone 172) recognizes Human Prolactin. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Prolactin is a peptide hormone synthesised and secreted by lactotrope cells in the adenohypophysis (anterior pituitary gland). It is also produced in other tissues including the breast and the decidua. Pituitary prolactin secretion is regulated by neuroendocrine neurons in the hypothalamus, most importantly by neurosecretory dopamine neurons of the arcuate nucleus, which inhibit prolactin secretion. Prolactin is a single chain polypeptide of 199 amino acids with a molecular weight of about 24,000 daltons. Its structure is similar to that of growth hormone and placental lactogen. The molecule is folded due to the activity of three disulfide bonds. Significant heterogeneity of the molecule has been described, thus bioassays and immunoassays can give different results due to differing glycosylation, phosphorylation, sulfation, as well as degradation. The non-glycosylated form of prolactin is the dominant form of prolactin that is secreted by the pituitary gland. Increased serum concentrations of prolactin during pregnancy cause enlargement of the mammary glands of the breasts and increases the production of milk. However, the high levels of progesterone during pregnancy act directly on the breasts to stop ejection of milk. It is only when the levels of this hormone fall after childbirth that milk ejection is possible.

1. Paus, R. et al. (2012) Arch Dermatol Res. 304(2):115-8.
2. Zhu, Y. et al. (2008) Comp Biochem Physiol C Toxicol Pharmacol. 148(4):370-80.
3. Panina, S. et al. (2009) J Endocrinol. 201(1):115-28.
4. Neuwmann, ID. et al. (2009) Endocrinology. 150(4):1841-9.
5. Molitch MD., ME. (2005) Mayo Clinic Proceedings 80(8):1050-1057
6. Gout, PW. et al. (1980) Cancer Research 40:2433-36.